For people living with asthma, or newly diagnosed.
At a Glance
| Medical name | Asthma (bronchial asthma) |
| ICD-10 code | J45 |
| What it is | Chronic inflammatory airway disease causing episodes of wheezing, coughing, chest tightness, and shortness of breath |
| How common | ~8–12% of South African adults; 10–15% of children. Estimated 3–4 million South Africans |
| Chronic Disease List | CDL 001 — all schemes must fund inhaled corticosteroids and reliever therapy |
| Standard controller | Inhaled corticosteroid (ICS) — beclomethasone or budesonide (~R180–R350/month) |
| Annual management cost | R4,600 (mild, well-controlled) to R194,000 (severe requiring biologic therapy) |
| Main financial risk | Acute exacerbations requiring hospital admission; biologic therapy for severe asthma (~R8,000–R15,000/month, not CDL-funded) |
Understanding Asthma
Asthma is a chronic inflammatory condition of the airways. The inflammation makes airways hypersensitive — they narrow more than normal in response to triggers, and they produce excess mucus. This narrowing causes the characteristic symptoms: wheezing, coughing (especially at night or after exercise), chest tightness, and shortness of breath.
Asthma is not a single, uniform disease. It ranges from mild (occasional symptoms triggered by colds or exercise, well-controlled with a low-dose inhaler) to severe (persistent symptoms despite high-dose treatment, frequent hospitalisations, requiring biologic medication).
Key distinctions
Allergic asthma: triggered by allergens (pollen, dust mites, animal dander, mould). Very common in SA. High IgE levels on blood test.
Non-allergic asthma: triggered by cold air, exercise, respiratory infections, irritants (smoke, chemicals). No specific allergen.
Severe refractory asthma: difficult-to-control asthma despite maximum conventional therapy. Small proportion (~5–10%) but responsible for most hospital admissions and costs.
Treatment in South Africa
South Africa follows the SA Thoracic Society (SATS) 2021 guidelines, aligned with the GINA 2024 global strategy.
The core principle: every asthma patient should have a controller inhaler (ICS), not just a reliever (SABA). Reliever-only management (using only a salbutamol "blue pump") is outdated and associated with more exacerbations. GINA 2024 no longer recommends SABA monotherapy as first-line even for mild asthma.
Track 1 (preferred internationally): as-needed low-dose ICS-formoterol combination inhaler — used as both controller and reliever. Single inhaler for all purposes.
Track 2 (common in SA due to cost): daily low-dose ICS (beclomethasone) + as-needed SABA (salbutamol). Two separate inhalers. Lower cost than Track 1 and effective when used correctly.
Medication Cost Table (2026 Estimates)
| Medication | Class | Monthly Cost | CDL Funded |
|---|---|---|---|
| Beclomethasone 100mcg MDI (generic) | ICS (controller) | ~R180 | Yes |
| Salbutamol 100mcg MDI (generic) | SABA (reliever) | ~R90 | Yes |
| Budesonide/formoterol 160/4.5mcg (generic) | ICS-LABA (combination) | ~R350 | Scheme-dependent |
| Montelukast 10mg (generic) | LTRA (add-on) | ~R150 | Scheme-dependent |
| Omalizumab (Xolair) | Anti-IgE biologic | ~R8,000 | NOT CDL standard |
| Mepolizumab (Nucala) | Anti-IL-5 biologic | ~R10,000 | NOT CDL standard |
| Dupilumab (Dupixent) | Anti-IL-4/13 biologic | ~R15,000 | NOT CDL standard |
All costs are 2026 SEP estimates pending SAHPRA verification.
Annual Cost Breakdown
| Severity | Medication | Visits & Tests | Estimated Annual Total |
|---|---|---|---|
| Mild (ICS + SABA) | R3,240 | R1,400 | ~R4,640 |
| Moderate (ICS-LABA) | R5,760 | R2,880 | ~R8,640 |
| Severe (ICS-LABA + biologic) | R100,200–R184,200 | R8,800 | ~R110,000–R194,000 |
The biologic tier is the key financial discontinuity: moving from conventional to biologic therapy adds R96,000–R180,000 per year in medication costs, almost entirely OOP.
Your Medical Aid and Asthma
What your scheme must fund (CDL 001)
All registered medical schemes must fund asthma management at PMB level. This covers:
- GP consultations for asthma management
- Inhaled corticosteroid (ICS) — beclomethasone or budesonide (generic)
- Short-acting beta-agonist (SABA) reliever — salbutamol
- Spirometry (lung function testing)
- Specialist (pulmonologist) referral if poorly controlled or diagnostic uncertainty
What the CDL does NOT automatically fund: - Combination ICS-LABA inhalers (scheme-dependent — some require step-through separate ICS + SABA first) - Biologic therapies (omalizumab, mepolizumab, dupilumab) — NOT in CDL formulary; exceptional needs only - Allergy testing (skin prick tests, RAST/sIgE blood tests) — d2d benefit or OOP - Home nebuliser — scheme-dependent - Spacer device — typically funded as clinically indicated
Biologics and Severe Asthma
If your asthma is not controlled despite high-dose ICS-LABA therapy, a pulmonologist or allergologist may recommend a biologic. Before accessing scheme funding, you will typically need: 1. Pulmonologist assessment confirming severe refractory asthma 2. Documented phenotyping (elevated eosinophils for anti-IL-5; elevated IgE for anti-IgE; Type 2 inflammation for dupilumab) 3. Multiple failed trials of conventional therapy 4. Scheme exceptional needs committee approval
This process is lengthy and not guaranteed. Many patients with severe asthma self-fund biologic treatment or go undertreated.
The Gap Cover Question
For mild-to-moderate asthma: your ICS + SABA is CDL-funded. Annual costs are R4,600–R8,600. Gap cover is not relevant to routine asthma management.
For acute admissions: an acute asthma attack requiring hospital admission generates pulmonologist and emergency physician shortfalls. A severe attack requiring ICU admission (status asthmaticus) can produce R10,000–R30,000 in specialist shortfalls. Gap cover protects against this.
For severe asthma on biologics: the OOP exposure is the biologic medication cost, not specialist shortfalls. Gap cover does not address chronic medication OOP. The scheme coverage decision (exceptional needs approval) is the lever that matters here.
South African Sources
- SA Thoracic Society 2021 Position Statement on Asthma Management (PMC8802209)
- GINA 2024 Global Strategy for Asthma Management and Prevention
- Addressing the asthma crisis in Africa. Egyptian Journal of Internal Medicine, 2024
- Council for Medical Schemes: CDL 001 PMB Algorithm
Check your asthma cover on AURA →
Medical disclaimer: Educational purposes only. All medication costs are 2026 estimates pending SAHPRA SEP verification.